Ocular Myasthenia: How do I Treat?

Update Item Information
Identifier 20190318_nanos_hottopic1_02_slides
Title Ocular Myasthenia: How do I Treat?
Creator Michael S. Lee, MD
Affiliation University of Minnesota
Subject Ocular Myasthenia; Treatment; Therapy; Pyridostigmine; Corticosteroids; Thymectomy; Azathioprine; Mycophenolate Mofetil
Description Myasthenia gravis is caused by pathogenic autoantibodies to the postsynaptic neuromuscular junction. Clinically, this may affect any of the skeletal muscles causing variable weakness, which worsens with continued muscle activity. Ocular myasthenia gravis (OMG) may affect the levator palpebrae superioris, extraocular muscles, and orbicularis oculi causing ptosis and diplopia. Meanwhile, generalized myasthenia gravis (GMG) refers to involvement of the non-ocular skeletal muscles. This talk will focus on treatment strategies for OMG. Discussion of the diagnosis of OMG and the treatment of GMG is beyond the scope.
Date 2019-03
Language eng
Format application/pdf
Format Creation Microsoft PowerPoint
Type Text
Source 2019 North American Neuro-Ophthalmology Society Annual Meeting
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
ARK ark:/87278/s6qg42jc
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Setname ehsl_novel_nam
ID 1539212
Reference URL https://collections.lib.utah.edu/ark:/87278/s6qg42jc
Back to Search Results